Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)

Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin in the liver) in liver cirrhosis, thrombocytopenia develops, which is associated with the risk of periprocedural/perioperative bleeding compli...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, Yu. V. Khoronko, T. A. Deeva, K. A. Gulyaeva, V. T. Ivashkin
Format:	Article
Language:	Russian
Published:	Gastro LLC 2024-08-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	pico thrombocytopenia hemostasis bleeding complications thrombosis thrombocytopenia correction thrombopoietin receptor agonists tpo-ras eltrombopag lusutrombopag avatrombopag, romiplostim
Online Access:	https://www.gastro-j.ru/jour/article/view/1383
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease
by: Faisal Alsayegh, et al.
Published: (2025-01-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01)

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure
by: Davide Scalabrini, et al.
Published: (2023-08-01)

Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)

Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)

Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01)

PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA
by: Roberto Stasi, et al.
Published: (2009-11-01)

Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis
by: Xiaofang Zhang, et al.
Published: (2025-06-01)

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice
by: II Zotova, et al.
Published: (2017-01-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study
by: Takayoshi Suga, et al.
Published: (2025-01-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Acute myocardial infarction induced by avatrombopag: a case report
by: Gou Junqi, et al.
Published: (2025-08-01)

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Treatment of patients with refractory immune thrombocytopenia: literature review and case report
by: V. V. Ptushkin, et al.
Published: (2014-07-01)

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag
by: Antonella Sau, et al.
Published: (2025-04-01)

Guidelines of Russian Expert Council on diagnostic and therapy of patients with primary immunne thrombocytopenia
by: A. A. Maschan, et al.
Published: (2022-11-01)

Investigation of the <i>ABCB1</i> Gene Polymorphism and Food Effects on the Avatrombopag Pharmacokinetics in Chinese Individuals: A Population Pharmacokinetic/Pharmacodynamic Analysis
by: Xin Liu, et al.
Published: (2025-06-01)

Research progress in the treatment of chronic primary immune thrombocytopenia
by: HUANG Zhouxuan, et al.
Published: (2025-04-01)

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
by: María Henar García Lagunar, et al.
Published: (2015-02-01)

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01)

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01)

Analysis of the efficacy of avatrombopag for the delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation for aplastic anemia
by: Xinhe Zhang, et al.
Published: (2025-08-01)

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports
by: Waleed Ghanima, et al.
Published: (2025-12-01)

Fisher-Evans syndrome. Casereport in physician’s practice
by: A. A. Yakushev, et al.
Published: (2020-01-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
by: Vikas Talreja, et al.

The Effect of COVID‐19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real‐World Study in China
by: Yujiao Zhang, et al.
Published: (2025-04-01)

Differential diagnosis of thrombocytopenes
by: A. L. Melikyan, et al.
Published: (2017-04-01)

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks
by: Elif Habibe Aktekin, et al.
Published: (2025-12-01)

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy
by: VA Shuvaev, et al.
Published: (2017-10-01)